Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to Editors

A genetic insight into vitamin D binding protein and COVID-19

ARTICLE INFO

Keywords
- COVID-19
- DBP
- Genetic polymorphism
- Vitamin D
- Immune response
- Vitamin D deficiency

ABSTRACT

It’s since December 2019 that Corona virus disease (COVID-19) has emerged to be the global issue of concern. A “pandemic”; this is what WHO has declared about the COVID-19 outbreak on March 3rd, 2020. Vitamin D and its deficiency have recently been claimed to be one of the potential factors affecting COVID-19 risks and outcomes [1]. As Selberstein et al., has recently discussed the effect of vitamin D deficiency, and the role of vitamin D supplementation in COVID-19 patients [2], I’d believe that vitamin D binding protein (DBP) is maybe also involved. A closer look on DBP and its action on regulating the circulatory vitamin D levels, its polymorphisms and their impact on COVID-19 prevalence and mortality, will be briefly discussed.

Vitamin D deficiency is considered as a global pandemic, with more than one billion subjects affected [3]. This deficiency is even more obvious in patients with kidney diseases, lacking the 1-hydroxy activating step [4]. However, there is increasing body of evidence supporting the idea of the extra-renal vitamin D metabolism machinery, through extra-renal vitamin D receptors. These receptors are not only regulating the vitamin D circulatory levels [4], but also seems to play a critical role on its immunomodulatory responses [5].

Recently, vitamin D deficiency was accused to be a risk factor for COVID-19. Vitamin D could act as an inhibitor for the virus entry through interacting with the angiotensin converting enzyme-2 receptor (ACE2), the one that serves as the entry point for the virus which having its (S) protein spike [6]. Calcitriol or (di-hydroxy vitamin D) can exert pronounced effects on ACE2/Angiotensin (1–7)/Mas receptor axis, enhancing the expression of ACE2 [7]. However, ACE2 polymorphisms have also been reported in different populations [6]. Additionally, there are increasing evidences reporting the vitamin D modulationary response on the macrophages, preventing them from the extra release of inflammatory cytokines and chemokines (Cytokine storm) [8].

As there are already published data correlating vitamin D deficiency with severe COVID-19, and illustrating the role of vitamin D in both adaptive and innate immunity, various ongoing studies are also addressing the effect of vitamin D and vitamin D related gene polymorphisms on patients with COVID-19 [9,10].

Vitamin D binding protein (DBP); which is mainly produced in liver, is regulating vitamin D circulating metabolites (free and total metabolites)[11,12]. It’s worth noting that DBP is not influenced by vitamin D levels, but it’s regulated by estrogen, glucocorticoids and inflammatory cytokines.

Indeed, DBP is known to be the most polymorphic protein, with it different alleles that are substantially affecting its biologic functions [13]. There are two most common DBP alleles; rs7041 and rs4588, which have been implicated on the pathogenesis of various clinical conditions [11], mainly by their affinity to vitamin D. Higher plasma levels of 25-hydroxy vitamin D (25(OH)D) were shown to be associated with subjects having the AA genotype within the rs4588 locus. While patients with GG genotype have shown less 25(OH)D levels after same dose of vitamin D supplementation [13]. Interestingly, both allelic variants (rs7041 and rs4588) are also donated to be associated to chronic obstructive pulmonary disease (COPD) [14].

On the other hand, it was also noticed that rs7041 locus was found to be associated with higher susceptibility to hepatitis C viral infection [15]. As DBP gene polymorphisms have been greatly correlated with higher susceptibility of infections, and vitamin D deficiency in different population [16–18], they may also have a role in COVID-19.

There are different DBP isoforms influencing vitamin D serum concentration and its bio-availability [14]. By combining this information with the discussed role of vitamin D and its impact on the pathogenesis of COVID-19, I’d hypothesize that a more severe reaction against viral infections is modulated by the human immune system, if no necessary concentrations of bioavailable vitamin D presented.

A recent study has showed the rs7041 locus to be associated with increased risk of COVID-19 infection and mortality [19]. Therefore, the association of the genetic polymorphisms of DBP and COVID-19 may depend on the modulatory pleiotropic effects of the bioavailable vitamin D levels. However, there’s a genome-wide meta-analysis that has illustrated the DBP to have more four SNPs, which are also affecting the concentration of the 25(OH)D levels: rs2282679 (DBP), rs10741657 (near CYP2R1), rs12785878 (near DHCR7), and finally rs6013897 (at CYP24A1) [20].
In conclusion, I’d highlight the need for further genetic analysis regarding the actual role of DBP genetic variations on the bioavailable vitamin D levels. There’s also a need for more detailed studies regarding these genetic alleles, and their relation to the severity and mortality of COVID-19 infected patients. The use of both clinical research and genetic analysis may help us decipher the ambiguities of COVID-19 pandemic.

**Funding**

No source of funding or sponsorship.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

[1] Alshahawey M. COVID-19 and Vitamin D deficiency; the two pandemics. Are they correlated? Int J Vitam Nutr Res 2020;1:1–2.

[2] Silberstein M. Vitamin D: a simpler alternative to tocilizumab for trial in COVID-19? Med Hypotheses 2020;140:109767. https://doi.org/10.1016/j.mehy.2020.109767.

[3] Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocrine Metabolic Disorders 2017;18(2):153–65.

[4] Alshahawey M, El Wakeel L, Elsaid T, Sabri NA. The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: a randomized placebo controlled study. Nutrition, Metabolism and Cardiovascular Diseases. 2020.

[5] Azmi H, Hassou N, Ennaji MM. Vitamin D Immunomodulatory role in chronic and acute viral diseases. Emerging and Reemerging Viral Pathogens: Elsevier; 2020. p. 489-506.

[6] Alshahawey M, Raslan M, Sabri N. Sex-mediated effects of ACE2 and TMPRSS2 on the incidence and severity of COVID-19; the need for genetic implementation. Curr Res Transl Med 2020;68(4):149–50.

[7] Cui C, Xu P, Li G, Qiao Yi, Han W, Geng C, et al. Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: role of renin-angiotensin system. Redox Biol 2019;26:101295. https://doi.org/10.1016/j.redox.2019.101295.

[8] Helming L, Bose J, Ehrchen J, Schiebe S, Frahm T, Geffers R, et al. 1α, 25-dihydroxyvitamin D3 is a potent suppressor of interferon γ-mediated macrophage activation. Blood 2005;106:4351–8.

[9] Xu Yi, Baylink DJ, Chen C-S, Reeves ME, Xiao J, Lacy C, et al. The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuro-protective treatment for COVID-19. J Transl Med 2020;18(1). https://doi.org/10.1186/s12967-020-02488-5.

[10] Teymoori- Rad M, Marashi SM. Vitamin D and Covid-19: From potential therapeutic effects to unanswered questions. Rev Med Virol 2020;e2159.

[11] Bilde BD, Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Front Endocrinol 2019; 10:317.

[12] Chun RF, Peery BE, Orwell ES, Nielson CM, Adams JS, Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol 2014;144:132–7.

[13] Mehramiz M, Khayatzadeh SS, Esmaeily H, Ghasemi F, Sadeghi-Ardekani K, Teyf M, et al. Associations of vitamin D binding protein variants with the vitamin D-induced increase in serum 25-hydroxyvitamin D. Clin Nutr ESPEN 2019;29:59–64.

[14] Khanna R, Nandy D, Senapati S. Systematic review and meta-analysis to establish the association of common genetic variations in Vitamin D binding protein with chronic obstructive pulmonary disease. Front Genet 2019;10:413.

[15] Xie C-N, Yue M, Huang P, Tian T, Fan H-Z, Wu M-P, et al. Vitamin D binding protein polymorphisms influence susceptibility to hepatitis C virus infection in a high-risk Chinese population. Gene 2018;679:405-11.

[16] Takiar R, Lutsey PL, Zhao Di, Guallar E, Schneider ALC, Grans ME, et al. The associations of 25-hydroxyvitamin D levels, vitamin D binding protein gene polymorphisms, and race with risk of incident fracture-related hospitalization: twenty-year follow-up in a bi-ethnic cohort (the ARIC Study). Bone 2015;78:94-101.

[17] Michos ED, Misialek JR, Selvin E, Folsom AR, Pankow JS, Post WS, et al. 25-hydroxyvitamin D levels, vitamin D binding protein gene polymorphisms and incident coronary heart disease among whites and blacks: the ARIC study. Atherosclerosis 2015;241(1):12–7.

[18] Khan AH, Jafri L, Siddiqui A, Naureen G, Morris H, Moatter T. Polymorphisms in the GC gene for vitamin D binding protein and their association with vitamin D and bone mass in young adults. Metabolism 2019;9:11.

[19] Karcioglu Batur L, Hekim N. The role of DBP gene polymorphisms in the prevalence of new coronavirus disease 2019 infection and mortality rate. J Med Virol 2020;93(3):1409–13.

[20] Wang T, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. The Lancet 2010;376(9736):180–8.

Mona Alshahawey*

Department of Clinical Pharmacy, Faculty of Pharmacy Ain Shams University, Cairo, Egypt

* Address: Building 13, Omar Bin Khattab St., Sefarat District, Nasr City, Cairo, Egypt.

E-mail address: mona.elshahawy@pharm.asu.edu.eg.